Johanniter GmbH Johanniter-Krankenhaus

Verified siteinfo

Germany Johanniterstrasse 3-5, Zentrum, 53113 Bonn, Germany

11 trials recruiting
Plasma cell myeloma · Non-small cell lung cancer · Colorectal cancer metastatic
Adult patients

About Specializations

Johanniter GmbH Johanniter-Krankenhaus in Bonn, Germany specialises in clinical trials of conditions such as Plasma cell myeloma, Non-small cell lung cancer, Colorectal cancer metastatic, Acute lymphocytic leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Gastroenterology and Surgical Innovations

The medical center is at the forefront of gastroenterology research, with a particular focus on improving surgical outcomes for complex procedures such as pancreatoduodenectomy. The center's research aims to enhance patient recovery and reduce complications associated with these surgeries.

Delayed Gastric Emptying (DGE) Management
Transcutaneous Nicotine Administration
Postoperative Recovery Optimization

Through innovative approaches like the transcutaneous administration of nicotine, the center is exploring new methods to mitigate the severity of DGE, thereby contributing to the advancement of surgical care and patient quality of life.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Johanniterstrasse 3-5, Zentrum53113 BonnGermany

Open in maps ↗

Recruiting now: 11 trials
Conditions studied: 25
Partner status: Verified site

More sites in Bonn Germany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

22 clinical trials

Bladder transitional cell carcinoma+1

Recruiting

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Enfortumab Vedotin
Sponsor:Eli Lilly & Co.

Contact Research Centre

Cachexia

Recruiting

A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

Investigational

A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Visugromab
Sponsor:CatalYm GmbH

Contact Research Centre

Colorectal cancer metastatic

Recruiting

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Summit Therapeutics Inc.

Contact Research Centre

Hormone-dependent prostate cancer

Recruiting

Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

Registered drugNo placebo

Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Apalutamide

Contact Research Centre

Breast cancer+4

Recruiting

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Elacestrant
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Hodgkin's disease

Recruiting

A Study of Pembrolizumab and Radiotherapy for Patients with Early-Stage Favorable Classic Hodgkin Lymphoma

Registered drugNo placebo

A Study of Pembrolizumab and Radiotherapy for Patients with Early-Stage Favorable Classic Hodgkin Lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:University Of Cologne

Contact Research Centre

Diffuse large B-cell lymphoma

Recruiting

Study Comparing Zilovertamab Vedotin with Drug Combination for Untreated Patients with Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

Study Comparing Zilovertamab Vedotin with Drug Combination for Untreated Patients with Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Acute lymphocytic leukaemia

Recruiting

Study on Ponatinib and Imatinib for Adults with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo

Study on Ponatinib and Imatinib for Adults with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo

Germany

Participants:18–64 years
Substances:Blinatumomab
Sponsor:Goethe University Frankfurt

Contact Research Centre

Colorectal cancer metastatic

Recruiting

Study on Chemotherapy with Irinotecan, Fluorouracil, and Oxaliplatin for Patients with Metastatic Colorectal Cancer After Surgery or Ablation

Registered drugNo placebo

Study on Chemotherapy with Irinotecan, Fluorouracil, and Oxaliplatin for Patients with Metastatic Colorectal Cancer After Surgery or Ablation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Charite Universitaetsmedizin Berlin KöR

Contact Research Centre

Plasma cell myeloma

Recruiting

Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo

Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Dexamethasone
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo

Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Infliximab
Sponsor:AstraZeneca AB

Contact Research Centre

Endometrial cancer+3

Not yet recruiting

Study of Disitamab Vedotin for Adults with Previously Treated HER2-Positive Solid Tumors, Including Lung, Head and Neck, Ovarian, and Endometrial Cancers

InvestigationalNo placebo

Study of Disitamab Vedotin for Adults with Previously Treated HER2-Positive Solid Tumors, Including Lung, Head and Neck, Ovarian, and Endometrial Cancers

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Disitamab Vedotin
Sponsor:Seagen Inc.

Contact Research Centre

Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites